Shanghai Jiao Tong University School of Medicine — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Da-Cheng-Qi Decoction Plus Standard Western TreatmentThis single-center prospective randomized controlled trial evaluated Da-Cheng-Qi Decoction (DCQD) as the acute-stage intervention of an integrated traditional Chinese and Western medicine whole-stage treatment protocol for severe acute pancreatitis (SAP). Sixty adults with SAP and intra-abdominal hypertension (IAP ≥ 12 mmHg) were randomized within 72 h of onset to receive standard Western treatment plus DCQD (100 mL via nasogastric tube twice daily for 7 days) or standard Western treatment alone. The primary outcome was intra-abdominal pressure measured by standardized bladder manometry every 12 h for 7 days. Secondary outcomes included stool output, length of hospital and ICU stay, and 28-day mortality. The trial was conducted at the Emergency Intensive Care Unit of Ruijin Hospital between April 2026 and July 2026.	Hypertension, Myopathies	Non applicable	Traitement symptomatique	China	À vérifier
Umbilical cord mesenchymal stromal cell-derived exosomes (UCMSC-Exo)The goal of this clinical trial is to learn if intranasal umbilical cord mesenchymal stromal cell-derived exosomes (UCMSC-Exo) are safe and can help treat early Parkinson's disease in adults aged 50-75. It will also learn about the safety and tolerability of UCMSC-Exo. This is a single-center, open-label, dose-escalation study using a 3+3 design; there is no placebo and no blinding. The main questions it aims to answer are: 1. What local and systemic adverse events and serious adverse events occur with intranasal UCMSC-Exo? 2. Does intranasal UCMSC-Exo improve motor and non-motor symptoms, biomarkers, and imaging measures in Parkinson's disease? 3. Researchers will compare low-, medium-, and high-dose UCMSC-Exo groups sequentially to assess safety and preliminary efficacy. Participants will: 1. Receive UCMSC-Exo by nasal spray twice weekly (Monday/Thursday) for 12 weeks (24 administrations) at their assigned dose. 2. Continue their usual dopaminergic medication during the study. 3. Visit the clinic for safety assessments at weeks 4, 12, 16, and 48, and for efficacy assessments at weeks 12, 16, 24, 36, and 48. 4. Undergo blood sampling, symptom questionnaires, and PET-MR imaging at scheduled time points. 5. Be followed for a total of 48 weeks, including the 12-week treatment period and 36 weeks after treatment.	Parkinson	Phase 1/2	Thérapie cellulaire + Traitement symptomatique	China	À vérifier
Da-Cheng-Qi Decoction Plus Standard Western TreatmentThis single-center prospective randomized controlled trial evaluated Da-Cheng-Qi Decoction (DCQD) as the acute-stage intervention of an integrated traditional Chinese and Western medicine whole-stage treatment protocol for severe acute pancreatitis (SAP). Sixty adults with SAP and intra-abdominal hypertension (IAP ≥ 12 mmHg) were randomized within 72 h of onset to receive standard Western treatment plus DCQD (100 mL via nasogastric tube twice daily for 7 days) or standard Western treatment alone. The primary outcome was intra-abdominal pressure measured by standardized bladder manometry every 12 h for 7 days. Secondary outcomes included stool output, length of hospital and ICU stay, and 28-day mortality. The trial was conducted at the Emergency Intensive Care Unit of Ruijin Hospital between April 2026 and July 2026.	Myopathies	Non applicable	Traitement symptomatique	China	À vérifier
Umbilical cord mesenchymal stromal cell-derived exosomes (UCMSC-Exo)The goal of this clinical trial is to learn if intranasal umbilical cord mesenchymal stromal cell-derived exosomes (UCMSC-Exo) are safe and can help treat early Parkinson's disease in adults aged 50-75. It will also learn about the safety and tolerability of UCMSC-Exo. This is a single-center, open-label, dose-escalation study using a 3+3 design; there is no placebo and no blinding. The main questions it aims to answer are: 1. What local and systemic adverse events and serious adverse events occur with intranasal UCMSC-Exo? 2. Does intranasal UCMSC-Exo improve motor and non-motor symptoms, biomarkers, and imaging measures in Parkinson's disease? 3. Researchers will compare low-, medium-, and high-dose UCMSC-Exo groups sequentially to assess safety and preliminary efficacy. Participants will: 1. Receive UCMSC-Exo by nasal spray twice weekly (Monday/Thursday) for 12 weeks (24 administrations) at their assigned dose. 2. Continue their usual dopaminergic medication during the study. 3. Visit the clinic for safety assessments at weeks 4, 12, 16, and 48, and for efficacy assessments at weeks 12, 16, 24, 36, and 48. 4. Undergo blood sampling, symptom questionnaires, and PET-MR imaging at scheduled time points. 5. Be followed for a total of 48 weeks, including the 12-week treatment period and 36 weeks after treatment.	Parkinson	Phase 1/2	Thérapie cellulaire + Traitement symptomatique	China	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Umbilical cord mesenchymal stromal cell-derived exosomes (UCMSC-Exo)	Parkinson	Phase 1/2	NCT07923838	UC-MSC-Exos PD — Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease	ACTIVE_NOT_RECRUITING
Da-Cheng-Qi Decoction Plus Standard Western Treatment	Myopathies	Non applicable	NCT07816900	Efficacy and Safety of Da-Cheng-Qi Decoction in Severe Acute Pancreatitis	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.